Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | JAK1 | P23458 | 14/20 | 0.45 |
| ▸ | JAK2 | O60674 | 13/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | CTSD | P07339 | 2/20 | 0.41 |
| ▸ | CTSL | P07711 | 2/20 | 0.41 |
| ▸ | CTSB | P07858 | 2/20 | 0.41 |
| ▸ | CTSS | P25774 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29187312 | 0.86 | JAK1 (0.45) | JAK1JAK2 | |
| SCHEMBL21775669 | 0.85 | JAK1 (0.42) | USP2SMN1; SMN2JAK1JAK2 | |
| SCHEMBL16989670 | 0.84 | JAK1 (0.48) | JAK1JAK2 | |
| SCHEMBL31479119 | 0.81 | USP2 (0.47) | USP2SMN1; SMN2JAK1JAK2 | |
| SCHEMBL17009092 | 0.76 | JAK1 (0.44) | JAK1JAK2 | |
| SCHEMBL9921830 | 0.75 | MEN1 (0.44) | USP2SMN1; SMN2JAK1JAK2 | |
| SCHEMBL2398369 | 0.74 | USP2 (0.59) | USP2SMN1; SMN2JAK1JAK2RECQL | |
| SCHEMBL26148291 | 0.74 | MEN1 (0.43) | USP2SMN1; SMN2JAK1JAK2 | |
| SCHEMBL25270241 | 0.72 | MEN1 (0.45) | USP2SMN1; SMN2JAK1JAK2 | |
| SCHEMBL344191 | 0.72 | SMN1; SMN2 (0.96) | USP2SMN1; SMN2RECQLCTSDCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242530-A1 | 8-(AZETIDIN-1-YL)-[1,2,4]TRIAZOLO[1,5-A]PYRIDINYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2023-08-03 | — | — | US | disclosed |
| US-20230242530-A1 | 8-(AZETIDIN-1-YL)-[1,2,4]TRIAZOLO[1,5-A]PYRIDINYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2023-08-03 | — | — | US | disclosed |
| US-20230242530-A1 | 8-(AZETIDIN-1-YL)-[1,2,4]TRIAZOLO[1,5-A]PYRIDINYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2023-08-03 | — | — | US | disclosed |
| EP-4198036-A1 | 8-(AZETIDIN-1-YL)-[1,2,4]TRIAZOLO[1,5-A] PYRIDINYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | F. Hoffmann-La Roche AG (CH) | 2023-06-21 | — | — | EP | disclosed |
| EP-4198036-A1 | 8-(AZETIDIN-1-YL)-[1,2,4]TRIAZOLO[1,5-A] PYRIDINYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | F. Hoffmann-La Roche AG (CH) | 2023-06-21 | — | — | EP | disclosed |
| EP-3510030-B1 | 8-(AZETIDIN-1-YL)-[1,2,4]TRIAZOLO[1,5-A]PYRIDINYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | HOFFMANN LA ROCHE (CH) | 2023-03-22 | — | — | EP | disclosed |
| CN-109890817-B | 8- (azetidin-1-yl) - [1,2,4] triazolo [1,5-a ] pyridinyl compounds, compositions, and methods of use thereof | 豪夫迈·罗氏有限公司 | 2022-06-17 | — | — | CN | disclosed |
| US-20200270248-A1 | 8-(AZETIDIN-1-YL)-[1,2,4]TRIAZOLO[1,5-A]PYRIDINYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2020-08-27 | — | — | US | disclosed |
| US-20200270248-A1 | 8-(AZETIDIN-1-YL)-[1,2,4]TRIAZOLO[1,5-A]PYRIDINYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2020-08-27 | — | — | US | disclosed |
| EP-3510030-A1 | 8-(AZETIDIN-1-YL)-[1,2,4]TRIAZOLO[1,5-A]PYRIDINYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | H. Hoffnabb-La Roche Ag (CH) | 2019-07-17 | — | — | EP | disclosed |
| US-20190202822-A1 | 8-(AZETIDIN-1-YL)-[1,2,4]TRIAZOLO[1,5-A]PYRIDINYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2019-07-04 | — | — | US | disclosed |
| US-20190202822-A1 | 8-(AZETIDIN-1-YL)-[1,2,4]TRIAZOLO[1,5-A]PYRIDINYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2019-07-04 | — | — | US | disclosed |
| WO-2018046409-A1 | 8-(AZETIDIN-1-YL)-[1,2,4]TRIAZOLO[1,5-A]PYRIDINYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2018-03-15 | — | — | WO | disclosed |
| WO-2018046409-A1 | 8-(AZETIDIN-1-YL)-[1,2,4]TRIAZOLO[1,5-A]PYRIDINYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2018-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190202822-A1 | 8-(AZETIDIN-1-YL)-[1,2,4]TRIAZOLO[1,5-A]PYRIDINYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | JAK1, JAK2, JAK3 | USP2 1763/4885SMN1; SMN2 3098/4885JAK1 1/4885 |
| US-20200270248-A1 | 8-(AZETIDIN-1-YL)-[1,2,4]TRIAZOLO[1,5-A]PYRIDINYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | JAK1, JAK2, JAK3 | USP2 1763/4885SMN1; SMN2 3098/4885JAK1 1/4885 |
| US-20230242530-A1 | 8-(AZETIDIN-1-YL)-[1,2,4]TRIAZOLO[1,5-A]PYRIDINYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | JAK1, JAK2, JAK3 | USP2 1763/4885SMN1; SMN2 3098/4885JAK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.